Eli Lilly partners with Hims & Hers to expand access to obesity medicines

Bitget2026/11/06 11:48

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Eli Lilly entered an agreement with Hims & Hers to expand access to its FDA-approved obesity medicines Zepbound and Foundayo.
Eligible patients prescribed either treatment can obtain home delivery without leaving the Hims & Hers platform.
Monthly self-pay prices start at $149 for Foundayo and $299 for Zepbound, matching prices available to any patient.
Hims & Hers committed not to offer compounded copies of Lilly's GLP-1 medicines; the agreement preserves independent prescribing decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: DE90839) on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Eli Lilly partners with Hims & Hers to expand access to obesity medicines

You may also like

Crypto prices